Literature DB >> 27499141

Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov.

Enrico Tortoli1, Thomas A Kohl2, Barbara A Brown-Elliott3, Alberto Trovato1, Sylvia Cardoso Leão4, Maria Jesus Garcia5, Sruthi Vasireddy3, Christine Y Turenne6, David E Griffith7, Julie V Philley7, Rossella Baldan1, Silvia Campana8, Lisa Cariani9, Carla Colombo10, Giovanni Taccetti8, Antonio Teri9, Stefan Niemann2, Richard J Wallace3, Daniela M Cirillo1.   

Abstract

The taxonomic position of members of the Mycobacterium abscessus complex has been the subject of intensive investigation and, in some aspects confusion, in recent years as a result of varying approaches to genetic data interpretation. Currently, the former species Mycobacterium massiliense and Mycobacterium bolletii are grouped together as Mycobacterium abscessus subsp. bolletii. They differ greatly, however, as the former M. bolletii has a functional erm(41) gene that confers inducible resistance to macrolides, the primary therapeutic antimicrobials for M. abscessus, while in the former M. massiliense the erm(41) gene is non-functional. Furthermore, previous whole genome studies of the M. abscessus group support the separation of M. bolletii and M. massiliense. To shed further light on the population structure of Mycobacterium abscessus, 43 strains and three genomes retrieved from GenBank were subjected to pairwise comparisons using three computational approaches: verage ucleotide dentity, enome to enome istance and single nucleotide polymorphism analysis. The three methods produced overlapping results, each demonstrating three clusters of strains corresponding to the same number of taxonomic entities. The distances were insufficient to warrant distinction at the species level, but met the criteria for differentiation at the subspecies level. Based on prior erm(41)-related phenotypic data and current genomic data, we conclude that the species M. abscessus encompasses, in adjunct to the presently recognized subspecies M. abscessus subsp. abscessus and M. abscessus subsp. bolletii, a third subspecies for which we suggest the name M. abscessus subsp. massiliense comb. nov. (type strain CCUG 48898T=CIP 108297T=DSM 45103T=KCTC 19086T).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27499141     DOI: 10.1099/ijsem.0.001376

Source DB:  PubMed          Journal:  Int J Syst Evol Microbiol        ISSN: 1466-5026            Impact factor:   2.747


  61 in total

1.  Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Authors:  Valerie Waters; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

2.  Comparing the Utilities of Different Multilocus Sequence Typing Schemes for Identifying Outbreak Strains of Mycobacterium abscessus subsp. massiliense.

Authors:  Aristine Cheng; Hsin-Yun Sun; Yi-Tzu Tsai; Shu-Yuan Chang; Un-In Wu; Po-Ren Hsueh; Wang-Huei Sheng; Yee-Chun Chen; Shan-Chwen Chang
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

3.  Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Soyoun Shin; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

4.  Genome-Based Taxonomic Classification of the Phylum Actinobacteria.

Authors:  Imen Nouioui; Lorena Carro; Marina García-López; Jan P Meier-Kolthoff; Tanja Woyke; Nikos C Kyrpides; Rüdiger Pukall; Hans-Peter Klenk; Michael Goodfellow; Markus Göker
Journal:  Front Microbiol       Date:  2018-08-22       Impact factor: 5.640

5.  Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.

Authors:  Bumhee Yang; Byung Woo Jhun; Seong Mi Moon; Hyun Lee; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Su-Young Kim; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 6.  Myxobacteria and their products: current trends and future perspectives in industrial applications.

Authors:  Akansha Shrivastava; Rakesh Kumar Sharma
Journal:  Folia Microbiol (Praha)       Date:  2021-05-31       Impact factor: 2.099

Review 7.  Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory.

Authors:  Deirdre L Church; Lorenzo Cerutti; Antoine Gürtler; Thomas Griener; Adrian Zelazny; Stefan Emler
Journal:  Clin Microbiol Rev       Date:  2020-09-09       Impact factor: 26.132

Review 8.  Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Authors:  Valerie Waters; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2016-12-19

9.  New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates.

Authors:  Amit Kaushik; Nicole C Ammerman; Nicole M Parrish; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

10.  Antimicrobial Susceptibility and Phylogenetic Relations in a German Cohort Infected with Mycobacterium abscessus.

Authors:  Nils Wetzstein; Thomas A Kohl; Tilman G Schultze; Sönke Andres; Carla Bellinghausen; Christian Hügel; Volkhard A J Kempf; Annette Lehn; Michael Hogardt; Hubert Serve; Maria J G T Vehreschild; Timo Wolf; Stefan Niemann; Florian P Maurer; Thomas A Wichelhaus
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.